Interestingly, studies have shown that neuroblastoma cells derived from MYCN transgenic mice with TP53 genetic mutations exhibit reduced sensitivity to MDM2 inhibitors (MI-63 and RG7388) compared with TP53 wild-type human neuroblastoma cells.72 This evidence concerns the gene TP53 and neuroblastoma.